NICE has recommended the first CAR T-cell therapy, Yescarta for the treatment of some lymphomas in a...
Read moreNICE have recommended Enhertu for the treatment of HER2-positive breast cancer within a managed acce...
Read moreOur experts provide an overview of the five key trends that could shape the pricing and market acces...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreWe summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...
Read moreWe discuss gene therapy pricing and reimbursement, manufacturing methods, analytical analysis, and k...
Read moreOur experts reflect on the trends that shaped the European pricing and market access landscape in 20...
Read moreWe summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...
Read moreIntroduction The European landscape has seen both approvals and withdrawals of cell and gene therapi...
Read moreWe look at whether payers are willing to pay for innovative gene therapies & CAR-Ts and the impact o...
Read more